Incidence and determinants of Pseudomonas aeruginosa infection among persons with HIV: association with hospital exposure

Am J Infect Control. 2001 Apr;29(2):79-84. doi: 10.1067/mic.2001.110367.

Abstract

Background: Little information exists on risk factors for Pseudomonas aeruginosa infection in persons with HIV. We assessed the incidence and factors associated with P aeruginosa among persons with HIV enrolled in a large observational cohort study in Los Angeles.

Methods: Data were analyzed from 4825 persons aged > or =13 years with HIV infection enrolled from 4 outpatient facilities from 1990 to 1998. The association between P aeruginosa infection and demographic, risk behavior, and clinical factors was assessed.

Results: P aeruginosa was diagnosed in 72 (1.5%) patients representing a crude incidence rate of 0.74 per 100 person-years. The most frequent site of infection was pulmonary (47%). In multivariate analysis, prior hospitalization (adjusted rate ratio = 7.9, 95% CI, 3.8-16.2), and both dapsone (adjusted rate ratio = 4.0, 95% CI, 2.2-7.4) and trimethoprim-sulfamethoxazole (adjusted rate ratio = 2.5, 95% CI, 1.2-5.3) use were independently associated with higher rates of infection. Increasing days of inpatient stay (P <.01) and decreasing CD4(+) counts (P <.01) were strongly associated with P aeruginosa. Azithromycin use decreased the risk of infection by nearly 70%.

Conclusion: Although the overall observed incidence of P aeruginosa was low, hospital exposure, declining CD4(+) levels, and the use of dapsone or trimethoprim-sulfamethoxazole increased the risk of P aeruginosa disease, and azithromycin use was protective in this population. These findings may assist in the early recognition and diagnosis of persons likely to be at increased risk of P aeruginosa infection.

MeSH terms

  • AIDS-Related Opportunistic Infections / epidemiology*
  • AIDS-Related Opportunistic Infections / etiology*
  • AIDS-Related Opportunistic Infections / prevention & control
  • AIDS-Related Opportunistic Infections / transmission
  • Adolescent
  • Adult
  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / therapeutic use
  • Azithromycin / therapeutic use
  • CD4 Lymphocyte Count
  • Cohort Studies
  • Cross Infection / epidemiology*
  • Cross Infection / etiology*
  • Cross Infection / prevention & control
  • Cross Infection / transmission
  • Dapsone / adverse effects
  • Female
  • Health Behavior
  • Hospitalization / statistics & numerical data*
  • Humans
  • Incidence
  • Infection Control
  • Length of Stay / statistics & numerical data
  • Los Angeles / epidemiology
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Pseudomonas Infections / epidemiology*
  • Pseudomonas Infections / etiology*
  • Pseudomonas Infections / prevention & control
  • Pseudomonas Infections / transmission
  • Pseudomonas aeruginosa
  • Risk Factors
  • Risk-Taking
  • Trimethoprim, Sulfamethoxazole Drug Combination / adverse effects

Substances

  • Anti-Bacterial Agents
  • Trimethoprim, Sulfamethoxazole Drug Combination
  • Azithromycin
  • Dapsone